Scientists have identified eight distinct genetic "footprints" that are responsible for about 85% of prostate cancer cases, according to a new study published in the journal Nature. The research was conducted by the Pan Prostate Cancer Group (PPCG), which analyzed tumor tissue samples from 959 men. Four of these genetic footprints were linked to more aggressive tumors that are more likely to spread beyond the prostate gland. This discovery could lead to earlier detection of high-risk cancers and more tailored treatment strategies. Experts have called the findings "hugely exciting," as they offer new insights into the biological processes that drive prostate cancer. Ros Eeles, a professor of oncogenetics at The Institute of Cancer Research (ICR), pointed out that prostate cancer is not a single disease but a collection of different cancers that can develop and behave in various ways. The study also found that certain genetic footprints were associated with age and ancestry, including patterns that are more common in Black men. Colin Cooper, a professor of cancer genetics at the University of East Anglia, highlighted the importance of the international collaboration in uncovering these new biological insights. The research team plans to use these findings to develop classification systems for prostate cancer tumors based on molecular data. These systems could help doctors identify aggressive cancers earlier and make more informed decisions about personalized treatment. Lead author of the study, Professor Joachim Weischenfeldt from the University of Copenhagen, explained that the genetic fingerprints can help differentiate between patients who are likely to develop life-threatening cancer and those who are not. While more clinical studies are needed before these findings can be used in patient care, they represent an important step toward understanding the biology of aggressive prostate cancer and offering more personalized treatment options. Dr. Hayley Luxton from Prostate Cancer UK, which co-funded the study, said the findings could help men receive the personalized treatment they need for their prostate cancer. The PPCG has collected molecular data on more than 2,000 prostate cancers, and the next step is to use this information to develop and test new classification systems for prostate cancer tumors.